Principia Biopharma Reacquires Rights to Oral Immunoproteasome Program

NEXT STORY
Merus to Present at the Cowen & Co. 39th Annual Health Care Conference
PREV STORY
La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida 

author_avatar
NASDAQ Market News

Survey Finds Louisiana Residents Optimistic on Improving Individual Health; Struggle with Daily Routine, and Experience Cultural Obstacles

author_avatar
NASDAQ Market News

Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)

Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional ...

author_avatar
NASDAQ Market News